KOL EVENT MEETING MARCH 5, 2018 - An update on promising results with PRIMA in advanced dry-AMD - Pixium Vision
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
KOL EVENT MEETING
An update on promising results with PRIMA in
advanced dry-AMD
MARCH 5, 2018
KOL Meeting - Paris - March 5, 2019 1
Forward Looking Statements
T his doc um ent c o nta in s inf or m at ion on P ix iu m Vis ion ’s m ark ets and c om peti t i ve pos i t ion , and m ore s pec if ic a l l y, on th e s i ze of its m ark ets . T his i nf orm atio n h a s
been d ra wn f rom var io us s our c es o r f rom th e c om pani es o wn es t i m ates . In ves to rs s h ou ld not bas e the i r i n ve s tm ent dec is ion on th i s inf orm atio n . T h is d o c um ent
als o c ont a ins c e rta i n f or ward - look ing s ta tem ents . T hes e s tatem ent s are not gua rantees of the Com pan y's f utu re pe rf orm ance . T hes e f or wa rd- l ook ing stat em ents
r e late to th e Com pan y' s f utur e pr os pec ts , de ve lo pm ents and m ark etin g s trat eg y and are b as ed on an a l ys es of e arn ings f orec as ts and es tim ates of am ounts not ye t
determ i nab le . For wa r d - look ing s t atem ents ar e s ubj ec t to a va r iet y of ris k s and unc erta i nt ies as t he y re la te to f uture e ve nts and a re dependen t on c irc um s tanc es
that m a y o r m a y not m ater ia l i ze in the f uture . P ix i um V is ion dra ws yo u r a ttent i on to t he f ac t tha t as f or ward - loo k ing s ta tem ents c ann o t unde r a n y c i rc um s tanc e be
c ons true d as a guar a n tee of the Com pan y's f uture perf orm anc e an d that the Com pan y’ s ac tua l f inanc i a l pos it i on, res u l ts and c as h f l o w, as we l l as the tre nds in
the s ec t or in wh ic h th e C om pan y ope rate m a y d if f er m ater ia l l y f r om thos e p ropos ed o r ref l ec ted in the f or ward- lo ok ing s tatem ent s c onta in ed i n th i s do c um ent .
Furth erm ore, e ve n if Pix ium V is ion ’s f inanc ia l pos i t ion, res u lts , c as h- f lo ws and de v e lopm ents in the s ec t or in w hic h the C om pan y op e rates were to c onf orm to the
f or ward - look i ng s t ate m ents c onta ine d in th i s doc um ent, s uc h res u lts o r de v e lopm ents c a nnot b e c o ns tru ed as a re l i ab le ind ic a t ion of the C om pan y's f uture res u lt s
or d e ve lopm ents . T he C om pan y does no t u ndertak e a n y o b l igat i on to up date or t o c o nf irm pr oj ec t ions o r e s tim ates m ade b y ana l ys ts o r t o m ak e pub l ic an y
c orrec t i on to an y p r os pec t i ve inf or m at ion in orde r to ref lec t an e v ent or c irc um s tanc e t hat m a y oc c ur af ter th e date of th is pres e nt ati on . A des c r ipt io n of thos e
even ts tha t m a y ha ve a m ater i a l ad ve rs e ef fec t on the b us ines s , f i nanc ia l pos it i on o r res ults of P ix ium V is ion, or on its a b i l it y t o m eet its ta rgets , appea rs in th e
s ec ti ons " R is k Fac to r s " of its “ Doc um ent d e Bas e” f i led wi th th e F renc h Au tor i té de s Marc hés F inanc ie rs . B y at tend in g t h is p r es entat io n o r ac c ept i ng th is
doc um ent, you agr ee to be bound by the f oregoing res tric tions s et out above .
KOL Meeting - Paris - March 5, 2019 2
• A Bioelectronics company developing bionic vision systems to
compensate for severe vision loss or blindness
• PRIMA, miniaturized wireless implant, novel breakthrough
technology to treating blindness
• In clinical stage initially treating dry age-related macular
degeneration (dry-AMD), a significant unmet medical need
Corporate Presentation – February 2019 3
Agenda
▪ 8:30 Welcome & introduction
K. Ishaque, CEO Pixium Vision
▪ 8:35 PRIMA inventor’s motivation
Pr. D. Palanker
▪ 8:50 First in human study PRIMA in AMD
Pr. J-A. Sahel
▪ 9:05 Real world unmet medical need: Atrophic dry-AMD
Pr. F. Holz
▪ 9:20 Q&A
▪ 10:00 Close
KOL Meeting - Paris - March 5, 2019 4
PRIMA inventor’s motivation
Daniel Palanker, PhD
Professor Department of Ophthalmology, School of Medicine,
and Director Hansen Experimental Physics Laboratory,
Stanford University, California, USA
KOL Meeting - Paris - March 5, 2019 5
Photovoltaic Restoration of Sight
in Age-Related Macular Degeneration
Daniel Palanker
Department of Ophthalmology and
Hansen Experimental Physics Laboratory
Stanford University, CA
KOL Meeting - Paris - March 5, 2019 6
Subretinal Electrical Stimulation of the Bipolar Cells
Electric
current
Neural
signals
KOL Meeting - Paris - March 5, 2019 7
Photovoltaic Retinal Prosthesis: System Design
camera
dichroic mirror
Subretinal implant 880nm beam
KOL Meeting - Paris - March 5, 2019 8
1
0.9 20 mm pixels,
Restoration of central vision in AMD 0.8 8 levels of grey
0.7
0.6
acuity
0.5
0.4
0.3
0.2
0.1
0
0 10 20 30 40
eccentricity, degrees
KOL Meeting - Paris - March 5, 2019 9
Operation of Subretinal Photovoltaic Prosthesis
Advantages of the photovoltaic approach: 880 nm light
• Simplicity of the PV implant allows its
miniaturization and wireless operation. Neural signals
• Small size and lack of wires enables minimally
invasive surgery.
• Modular design enables enlarging visual field GCL
via small retinotomy.
• Image projection is naturally linked to eye
movements.
• System enables image processing (autofocus,
zoom, contrast enhancement, background
removal, etc.).
• System can be integrated with advanced INL
computer vision for naming the people,
reading the text and other advanced functions.
• Image can be transferred directly from a
computer to the video glasses for reading,
watching TV, etc.
KOL Meeting - Paris - March 5, 2019
100 mm 10Photovoltaic Retinal Prosthesis: System Design
KOL Meeting - Paris - March 5, 2019 11Benefits of the network-mediated retinal stimulation
RCS pON RCS pOFF
• Flicker fusion at high (>20Hz) frequencies (now confirmed in patients).
• Adaptation to static images.
• Antagonistic center-surround organization of receptive fields.
• ON and OFF responses.
• Linear and non-linear summation of subunits in RGC receptive fields,
which is essential for high acuity.
Natural
+ Prosthetic, 48mm pitch
• Spatial resolution matching the pixel pitch, at least up to 50 µm
(equivalent of 20/200 acuity in a human eye).
17mm 48mm
KOL Meeting - Paris - March 5, 2019 12Pilot clinical trial of the PRIMA system in patients with
geographic atrophy
2x2 mm array, 30 µm thick, 100 µm pixels
1 month post surgery
Implant appears thicker in OCT
due to refractive index difference
All patients perceive bright white-yellow patterns
of retinotopically correct shapes and locations.
KOL Meeting - Paris - March 5, 2019 13Tests of Prosthetic Vision
• Patients preferred frequency: 10 Hz and above (30 Hz).
• Minimum bar width: 1 pixel in all 4 patients with subretinal placement, 2 pixels in
one patient with intra-choroidal placement of the implant.
• Bar orientation: 88-96% correct in all 4 patients with subretinal placement.
• Visual acuity measured with Landolt C is only 10-30% below the theoretical
minimum for the 100 µm pixel size:
Theoretical maximum with 100 µm pixels 20/420 (1.32 logMAR), 1.0 pixel
Patient 2, pre-op: 20/800 (1.6 LogMAR) 20/550 (1.44 logMAR), 1.35 pixels
Opaque video goggles Patient 3, pre-op: 20/1000 (1.7 LogMAR) 20/500 (1.40 logMAR), 1.23 pixels
with a camera
Patient 5, pre-op: 20/500 (1.4 LogMAR) 20/460 (1.37 logMAR), 1.15 pixels
KOL Meeting - Paris - March 5, 2019 14Smaller pixels enabled by honeycomb arrays
0.5 A/cm2
mm
40 INL INL
20
0
-50 0 50 mm
• Stimulation thresholds greatly reduced
• Penetration depth and stimulation threshold do
not depend on pixel width!
DV=E·l=j · r · l,
j - current density, r - tissue resistivity,
l – length of the cell.
KOL Meeting - Paris - March 5, 2019 15Honeycomb Arrays
40 mm 30 mm 20 mm
6 weeks post implantation in RCS rats
DAPI – all nuclei, IBA1- microglia, GS -Müller glia
RGC
IPL
INL
Array
KOL Meeting - Paris - March 5, 2019 16Summary
✓ Subretinal pixels larger than 70 µm provide
sufficient penetration of electric field into the inner
retina.
✓ Clinical results with PRIMATM (100µm pix) are
very encouraging.
✓ Pixels smaller than 50 µm will be based on
honeycomb arrays.
✓ Ultimate goal: to achieve visual acuity >20/100
using 20 µm honeycomb pixels. About 10,000
pixels in a 2 mm array.
KOL Meeting - Paris - March 5, 2019 17First in human study PRIMA in AMD
José-Alain Sahel, MD
Professor and Chairman of the Department of Ophthalmology at
University of Pittsburgh Medical Center (UPMC), USA
Director of the Institut de la Vision (Sorbonne-Université/Inserm/CNRS),
Paris
Chairman of the Department of Ophthalmology at Centre Hospitalier
National d’Ophtalmologie des XV-XX, and Fondation ophtalmologique
Rothschild, Paris
KOL Meeting - Paris - March 5, 2019 18PRIMA System
▪ Designed to restore central vision within
geographic atrophy.
▪ Wireless subretinal chip with photodiodes
activated by near-infrared (NIR) light projected
from video glasses, Invented by Daniel
Palanker (Stanford)
▪ PRIMA chip replaces the lost photoreceptors
and stimulates the bipolar cells in the INL.
▪ The remaining retinal network preserves many
features of the natural signal processing.
KOL Meeting - Paris - March 5, 2019 19PRIMA system
Images captured by the camera integrated
into the augmented reality glasses are
projected onto the retina using pulsed near-
infrared (NIR) light.
NIR beam
Subretinal wireless photovoltaic chip converts
pulsed light into pulsed electric current in each
pixel to stimulate the adjacent inner retinal
neurons.
Subretinal implant
KOL Meeting - Paris - March 5, 2019 20Generating an ex vivo model of a degenerated primate retina
Vibratome section of the retina
ONL
Implant
INL
GCL
?
NF
Multi-electrode array
KOL Meeting - Paris - March 5, 2019 21Surgical procedure
Vitrectomy and Additional manual
Sub-retinal BSS detachment, if
injection needed
Subretinal insertion
Retinotomy outside
of the 2x2mm wide
of the atrophic area,
chip using specially
preserving the PRL
designed forceps
Positioning of the
Exchange of the
chip at the pre-
PFCL with air and
determined location
final tamponade.
under PFCL
KOL Meeting - Paris - March 5, 2019 22Early feasibility study design: safety and functionality
FEASIBILITY STUDY
Restoration of visual function in patients with advanced atrophic dry age related
macular degeneration using the PRIMA system: open-label, non-randomized
CRITERIA PRIMARY ENDPOINT
Safety and elicitation of visual perception by
• 5 eyes of 5 patients electrical stimulation of the PRIMA implant
• VA < 20/400 measured by Octopus Visual Field.
• GA of at least 3 Optic Disc
Diameters without any other Microperimetry to :
pathology
– Confirm the absolute scotoma in the
• No light perception in the
atrophic area
atrophic area
• Fellow eye with useful vision – Identify the main PRL to ensure its
preservation
KOL Meeting - Paris - March 5, 2019 23PRIMA implant in the atrophic macula PRIMA implant:
1 month post surgery
2x2 mm array, 30 µm thick,
with 378 pixels of 100 µm
Implant is located in the middle
of the geographic atrophy area,
in close proximity to the INL.
KOL Meeting - Paris - March 5, 2019 24Results
▪ 5 consecutive patients successfully implanted between December 2017 and June
2018 in Paris:
– 3 with silicone oil removed at week 4 / 2 with gas (C2F6 and SF6).
▪ Surgery duration < 2 hours.
▪ Complications:
– 1 intraoperative complication: movement of the patient head under local
anesthesia during implantation led to thin subretinal bleeding, which resolved
after 6 weeks.
– 1 SAE at day 1 - acute hypertony resolved 2 days later without consequence.
– 1 small migration of the chip due to early posture change after surgery. The chip
remained within the atrophic area.
– 1 retinal detachment one year after surgery, retina reattached, no impact on
implant
KOL Meeting - Paris - March 5, 2019 25Anatomical Results
P1 P4
6M 1M
P2 P5
6M 6W
P3
The implant appears in OCT twice thicker
6M
due to higher refractive index of Si
compared to that of the retinal tissue.
Dashed line indicates position of the back
side of the implant resting on Bruch’s
membrane.
KOL Meeting - Paris - March 5, 2019 26Visual acuity (ETDRS) Pre vs. Post implantation
Average VA without System - ETDRS
Pre-op Baseline Post-op 1st
measurement measurement after
surgery
PRIMA can be safely implanted under the atrophic macula while preserving the
residual natural peripheral visual acuity, measured via ETDRS
KOL Meeting - Paris - March 5, 2019 27Results
▪ No other serious post-operative complications during the follow up currently ranging from 4 to
10 months.
▪ No decrease in natural vision compared to pre-operative acuity.
▪ Patients are trained to use the system and progress to describe patterns, objects, letters, etc.
elicited via the PRIMA chip in atrophic areas of the macula.
▪ Objective vision tests were conducted using opaque glasses to prevent confusion with
residual natural vision.
KOL Meeting - Paris - March 5, 2019 28PRIMA central visual perception at 6 Months
• Octopus Visual Field Measurement*
• Fully opaque glasses: light perception via PRIMA chip only
P1 P2 P3 P4 P5
System ON
System OFF
*performance of the PRIMA chip and system without use of any peripheral remaining vision (only with fully opaque glasses)
KOL Meeting - Paris - March 5, 2019 29Tests of Prosthetic Vision
Acuity measured with Landolt C
Theoretical limit with 100 µm pixels 20/400 (1.30 logMAR), 1.0 pixel
Subject A : PRE-OP : CF 20/550 (1.44 logMAR), 1.35 pixels
Subject B : PRE-OP : HM 20/500 (1.40 logMAR), 1.23 pixels
Subject C : PRE-OP LogMAR 1.4 20/460 (1.37 logMAR), 1.15 pixels
15-35% below the theoretical limit of resolution for 100 µm pixels
KOL Meeting - Paris - March 5, 2019 30Control: System ON vs OFF
KOL Meeting - Paris - March 5, 2019 31Conclusions
▪ Subretinal implantation of the wireless PRIMA chip in atrophic dry AMD
is feasible and safe.
▪ No decrease in residual natural vision compared to pre-operative
visual acuity.
▪ ALL 5 patients reached the functional primary end point of the
feasibility study (visual perception in the former scotoma).
▪ PRIMA provided the best prosthetic visual acuity to date: 20/460 – only
15% below the theoretical limit for 100mm pixels.
▪ Most subjects recognize complex patterns close to the theoretical limit
of the implant resolution.
KOL Meeting - Paris - March 5, 2019 32Next Steps
▪ Similar feasibility study initiated in Pittsburgh, USA
(J. Martel, J.A. Sahel).
▪ European multicenter pivotal study is planned for 2019.
▪ Implants with smaller pixels are being developed and tested in
preclinical studies (Palanker’s group at Stanford).
KOL Meeting - Paris - March 5, 2019 33Real world unmet medical need: Atrophic dry-AMD
Frank G. Holz, MD
Chairman and Professor, Department of Ophthalmology, University of
Bonn, Germany
President Elect of European Society of Retinal Specialists
(EURETINA)
KOL Meeting - Paris - March 5, 2019 34Dry AMD /Geographic Atrophy
Frank G. Holz
University of Bonn, Germany
KOL Meeting - Paris - March 5, 2019 35AMD Progressive Visual Impairment
Loss of High Contrast BCVA
Metamorphopsia
(distortion)
Neovascular AMD
Early AMD Intermediate AMD Scotoma
Geographic (central blind spot)
Atrophy
» Late AMD severe loss of vision, independence, and quality of life, increased
rates of falls, depression, and institutionalization
KOL Meeting - Paris - March 5, 2019 36Therapy neovascular AMD
Introduction anti-VEGF-Therapy 10 years ago
KOL Meeting - Paris - March 5, 2019 37Age-related macular degeneration (AMD)
Dry AMD – major unmet need
• Leading cause of blindness
• Even with effective treatments for neovascular AMD,
atrophy is still the long-term outcome
• Chronic progressive neurodegenerative disease
• Many challenges including multifactorial pathogenesis
KOL Meeting - Paris - March 5, 2019 38Macular Function
Courtesy S. Trauzettel-Klosinski
KOL Meeting - Paris - March 5, 2019 39KOL Meeting - Paris - March 5, 2019 40
“Dry” Age-related macular degeneration (AMD)
“Geographic atrophy“
Drusen
Pigment abnormalities
Early/intermediate AMD Late-stage AMD
KOL Meeting - Paris - March 5, 2019 41Loss of RPE on FAF correlates with photoreceptor loss on
SD-OCT
S Schmitz-Valckenberg, M Fleckenstein, AP Göbel, TC Hohman, FG Holz. IOVS 52:1-6;2011
KOL Meeting - Paris - March 5, 2019 42Loss of RPE in FAF images correlates with loss of
photoreceptor function on microperimetry
KOL Meeting - Paris - March 5, 2019 43Spectri and Chroma Pooled Outcome:
Change in Best-Corrected Visual Acuity from Baseline to Week 48
0
Mean Change From Baseline in
ETDRS BCVA Letter Score
ETDRS letter score ∆
from BL
Lq4 −4.1 (n = 601)
-5 Lq6 −4.9 (n = 604)
∆ Means
vs Sham Pooled (95% CI) P value Sham −4.9 (n = 604)
▬ Lampalizumab 0.8 ETDRS letters (−0.4,
q4w 2.1) 0.20
▬ Lampalizumab 0.1 ETDRS letters (−1.2,
q6w 1.3) 0.94
-10
0 12 24 36 48
Time Since Randomization, weeks
Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, Brittain C,
Ferrara D, Gray S, Honigberg L, Martin J, Tong B, Ehrlich JS, Bressler NM;
Chroma and Spectri Study Investigators. JAMA Ophthalmol. 2018 May 2
44Structural Assessment - Imaging Modalities
Colour fundus photography Fundus autofluorescence Near-infrared reflectance
OCT-Angiography Fluorescein angiography SD-OCT/SS-OCT
KOL Meeting - Paris - March 5, 2019 45KOL Meeting - Paris - March 5, 2019 46
KOL Meeting - Paris - March 5, 2019 47
Geographic Atrophy Assessment
Fundus Autofluoresence Imaging
KOL Meeting - Paris - March 5, 2019 48Geographic Atrophy – Disease progression
KOL Meeting - Paris - March 5, 2019 49Geographic atrophy - Prognostic markers for disease
progression
1 mm²/year 2 mm²/year 5 mm²/year
➢High variability in GA progression rate
AREDS Lindblad et al. 2009, BDES Klein et al. 2008, BMES Joachim et al. 2013, FAM Holz et al. 2007,
GAIN Biarnes et al. 2015, GAP Schmitz-Valckenberg et al. 2016, GAS Sunness et al. 1999,
KOL Meeting - Paris - March 5, 2019 50Geographic Atrophy: Fundus Autofluorescence
Automated Detection and Quantification
Schmitz-Valckenberg S, Brinkmann CK, Alten F, Herrmann P, Stratmann NK, Göbel AP, Fleckenstein M, Diller M, Jaffe GJ, Holz FG. Invest Ophthalmol Vis Sci. 2011;52:7640-6
KOL Meeting - Paris - March 5, 2019 51Geographic atrophy (GA) - Morphologic markers for disease
progression
➢ Prognostic information for future disease progression
➢ Identification of patients at high risk loosing visual acuity / reading ability
➢ Unequal distribution of patients with risk-features in clinical trials may
counterfeit / obscure a therapeutic effect
Fleckenstein M, Mitchell P, Freund B, Sadda SR, Holz FG, Brittain C, Henry EC, Ferrara D.
Review. Ophthalmology 2017 S0161-6420(17)30968-5
KOL Meeting - Paris - March 5, 2019 52Geographic atrophy (GA) - Heterogeneity
Fleckenstein M, Adrion C, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HP,
Mansmann U, Holz FG, FAM-Study group. Invest Ophthalmol Vis Sci. 2010;50:3915-21
KOL Meeting - Paris - March 5, 2019 53Visual Function Outcome Measures
KOL Meeting - Paris - March 5, 2019 54Interventional GA trials
Oxidative stress Genetic predisposition Environment
Brimonidine 2 α-Lipoic Acid 2
OT-551 Tandospirone
2 Phase 2
3 Phase 3
Accumulation of cellular by-products
Emixustat MC-1101 2 GSK933776
Fenretinide ALK-001 RN6G
Inflammation Complement Cascade RPE impairment
Fluocinolone Metformin 2 APL-2 2 LFG316 CPCB-RPE1 2 MA09-hRPE
Oracea 3 Minocycline 2 CLG561 2 Eculizumab CNTO 2476 2 HuCNS-SC
Copaxone Sirolimus Zimura 2 Lampalizumab 3 NT-501
GA
55
FG Holz, EC Strauss, S Schmitz-Valckenberg, M van Lookeren Campagne. Ophthalmology 121:1079-1091;2014Lampalizumab: Selective Inhibitor of Complement Factor D, the Rate-limiting Enzyme of
the Alternative Complement Pathway
Scientific rationale: genetic evidence implicates complement cascade
dysregulation in GA/AMD1,2
Complement factor D: rate-limiting enzyme of the alternative
complement pathway with lowest plasma concentration of Complement Factor D Lampalizumab
complement proteins3,4
C3 Convertase
Lampalizumab: an antigen-binding fragment of a humanized
monoclonal antibody that inhibits complement factor D3,4
Phase 2 Mahalo: GA area progression from baseline to C5 Convertase
18 months was reduced by 20% in the monthly
lampalizumab-treated group versus sham5
Membrane attack complex
56GA Area Growth From Baseline Over Time to Week 48
2.5 Wk 48 ∆ from BL
Pooled Lq4 2.06 mm2 2.5
Wk 48 ∆ from BL
Mean Change from BL GA Area, mm2
Mean Change From Baseline GA Area, mm2 Lq6 2.05 mm2 Lq4 2.09 mm2
2.0 Lq6 2.02 mm2
2.0 Sham 1.98 mm2 Sham 1.93 mm2
1.5
1.0
0.5
1.5
0.0
0 12 24 36 48
Time Since Randomization, weeks
1.0
2.5
Wk 48 ∆ from BL
Mean Change from BL GA Area, mm2
Lq4 2.02 mm2
∆ Means Relative 2.0 Lq6 2.09 mm2
vs Sham Pooled (95% CI) Reduction P value
Sham 2.04 mm2
0.5 1.5
▬ Lampalizumab q4w 0.07 mm2 (−0.05, 0.19) −3.6% 0.247
1.0
▬ Lampalizumab q6w 0.07 mm2 (−0.05, 0.19) −3.5% 0.255
0.5
0.0
0.0
0 12 24 36 48 0 12 24 36 48
Time Since Randomization, weeks
Time Since Randomization, weeks
FG Holz et al. JAMA Ophthalmol 2018, 136(6):666-77
57Age-related macular degeneration (AMD)
Dry AMD – how to proceed
• See how C3-inhibition works in phase 3
• Role of the ARMS2/HTRA1 risk polymorphism?
• Identify new targets
• Restoring function with device
• Define acceptable endpoints for earlier intervention
KOL Meeting - Paris - March 5, 2019 58KOL Meeting - Paris - March 5, 2019 59
Earlier Intervention?
CFP FAF SD-OCT
KOL Meeting - Paris - March 5, 2019 60State of the Art
16 Mio €
Text
• oder
• Aufzählungen
11Thank you KOL Meeting - Paris - March 5, 2019 62
PRIMA device development plan in dry-AMD
Feasibility study Pivotal
study
6-m 1-y CE
results follow-up Mark*
2018 2019 2020 2021 2022
US FIH
Feasibility study
Accelerated Access Program PMA**
*CE Mark – EU regulatory approval to commercialize
**PMA – US FDA regulatory approval to commercialize
Corporate Presentation - February 2019 63KOL EVENT MEETING
An update on promising results with PRIMA in
advanced dry-AMD
MARCH 5, 2018
KOL Meeting - Paris - March 5, 2019 64You can also read
